Results 161 to 170 of about 15,945 (227)

Growth Hormone Secretagogues

Combinatorial Chemistry & High Throughput Screening, 2006
Growth hormone secretagogues (GHSs) are synthetic molecules that stimulate and amplify pulsatile pituitary growth hormone release, via a separate pathway distinct from GH releasing hormone/somatostatin. The activity of GHSs is not fully specific for GH secretion; some GHSs also have slight releasing activity on other pituitary hormones and mediate GH ...
Maria Luisa, Isidro, Fernando, Cordido
openaire   +2 more sources

GH Secretagogues in Aging

Journal of Anti-Aging Medicine, 2000
Growth hormone (GH) secretagogues (GHS) are synthetic peptidyl and nonpeptidyl molecules which possess strong, dose-dependent and reproducible GH-releasing activity, even after oral administration. GHS release GH via actions on specific receptors at the pituitary and, mainly, at the hypothalamic level.
Arvat E, Giordano R, Broglio F, Gianotti, L, Di Vito L, Bisi G, Papotti M, Muccioli, Deghenghi R, Ghigo, E., GRAZIANI, Andrea   +10 more
openaire   +2 more sources

New growth hormone secretagogues

Letters in Peptide Science, 2001
Starting from EP 51389, a potent growth hormone secretagogue (GHS), a new series of GHS has been designed, synthesized and tested. This series was built on a gem-diamino moiety and a structure activity relationship study was performed including N-methylation of the amide bonds.
Guerlavais, V, Boeglin, D, Fehrentz, JA, Deghenghi, R, LOCATELLI, VITTORIO, Martinez, J.   +5 more
openaire   +3 more sources

Insulin Secretagogues

Current Medical Research and Opinion, 2002
Existing oral insulin secretagogues, sulphonylureas, are associated with hyperinsulinaemia, risk of hypoglycaemia and weight gain. Furthermore, they are not able to offer durable glycaemic control in patents with type 2 diabetes and are associated with progressive decline of beta-cell function.
openaire   +3 more sources

Tripeptide growth hormone secretagogues

Bioorganic & Medicinal Chemistry Letters, 1998
A series of C-terminus capped dipeptides and tripeptides was synthesized as growth hormone (GH) secretagogues. Among them, tripeptide Aib-D-Trp-D-homoPhe-OEt showed low nanomolar activity in the rat pituitary assay. Thus, we have demonstrated that the GH secretagogue activity of the hexa-hepta-GH releasing peptides can be mimicked at the tripeptide ...
L, Yang, G, Morriello, Y, Pan, R P, Nargund, K, Barakat, K, Prendergast, K, Cheng, W W, Chan, R G, Smith, A A, Patchett   +9 more
openaire   +2 more sources

Highly potent growth hormone secretagogues

Bioorganic & Medicinal Chemistry Letters, 2007
During an effort to search for more potent growth hormone secretagogues, we discovered a class of compounds of which the best compound 8 was 7-fold more active in vitro than the best compound in the series we revealed before [Tata, J. R.; Lu, Z.; Jacks, T. M.; Schleim, K. D.; Cheng, K.; Wei, L.; Chan, W.-S.; Butler, B.; Tsou, N.; Leung, K.; Chiu, S.-H.
Zhijian, Lu, James R, Tata, Kang, Cheng, Liente, Wei, Wanda W-S, Chan, Bridget, Butler, Klaus D, Schleim, Thomas M, Jacks, Gerard, Hickey, Arthur A, Patchett   +9 more
openaire   +2 more sources

Diabetes, lipids, and adipocyte secretagogues

Biochemistry and Cell Biology, 2004
That obesity is associated with insulin resistance and type II diabetes mellitus is well accepted. Overloading of white adipose tissue beyond its storage capacity leads to lipid disorders in non-adipose tissues, namely skeletal and cardiac muscles, pancreas, and liver, effects that are often mediated through increased non-esterified fatty acid fluxes.
May, Faraj, Hui Ling, Lu, Katherine, Cianflone   +2 more
openaire   +2 more sources